New cGMP fermentation facility in the UK set to meet growing demand for drug substance production, supporting biopharma ...
The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.
The Series D financing will support the clinical development of two ADCs.
Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...
The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.